WallStreetZenWallStreetZen

NASDAQ: TARS
Tarsus Pharmaceuticals Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

TARS past revenue growth

How has TARS's revenue growth performed historically?
Company
-32.42%
Industry
145.73%
Market
17.2%
TARS's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
TARS's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance

TARS earnings and revenue history

Current Revenue
$17.4M
Current Earnings
-$135.9M
Current Profit Margin
-778.9%

TARS Return on Equity

Current Company
-74.3%
Current Industry
-63.5%
Current Market
188%
TARS's Return on Equity (-74.3%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when TARS announces earnings.

TARS Return on Assets

Current Company
-58.2%
Current Industry
2.9%
TARS is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

TARS Return on Capital Employed

Current Company
-57.99%
Current Industry
19.5%
TARS's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

TARS vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
TARS$17.45M-$131.13M-$135.89M-44.69%N/A
PRTA$91.37M-$152.07M-$147.03M+148.98%N/A
BLTE$0.00-$31.20M-$31.63MN/AN/A
SRRK$0.00-$155.82M-$165.79M-100.00%N/A
AUTL$1.70M-$152.71M-$208.38M+2.90%N/A
View Top Biotech Stocks

TARS earnings dates

Next earnings date
Jun 21, 2024

Tarsus Pharmaceuticals Earnings & Revenue FAQ

What were TARS's earnings last quarter?

On Invalid Date, Tarsus Pharmaceuticals (NASDAQ: TARS) reported Q4 2023 earnings per share (EPS) of -$1.27, up 159.18% year over year. Total Tarsus Pharmaceuticals earnings for the quarter were -$41.90 million. In the same quarter last year, Tarsus Pharmaceuticals's earnings per share (EPS) was -$0.49.

If you're new to stock investing, here's how to buy Tarsus Pharmaceuticals stock.

What was TARS's earnings growth in the past year?

As of Q2 2024, Tarsus Pharmaceuticals's earnings has grown year over year. Tarsus Pharmaceuticals's earnings in the past year totalled -$135.89 million.

What is TARS's earnings date?

Tarsus Pharmaceuticals's earnings date is Invalid Date. Add TARS to your watchlist to be reminded of TARS's next earnings announcement.

What was TARS's revenue last quarter?

On Invalid Date, Tarsus Pharmaceuticals (NASDAQ: TARS) reported Q4 2023 revenue of $13.08 million up 30.76% year over year. In the same quarter last year, Tarsus Pharmaceuticals's revenue was $10.00 million.

What was TARS's revenue growth in the past year?

As of Q2 2024, Tarsus Pharmaceuticals's revenue has grown -32.42% year over year. This is 178.15 percentage points lower than the US Biotechnology industry revenue growth rate of 145.73%. Tarsus Pharmaceuticals's revenue in the past year totalled $17.45 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.